Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Series

2022

Faculty and Student Publications

Nanoemulsion

Articles 1 - 2 of 2

Full-Text Articles in Medicine and Health Sciences

Cannabidiol Loaded Topical Ophthalmic Nanoemulsion Lowers Intraocular Pressure In Normotensive Dutch-Belted Rabbits, Samir Senapati, Ahmed Adel Ali Youssef, Corinne Sweeney, Chuntian Cai Dec 2022

Cannabidiol Loaded Topical Ophthalmic Nanoemulsion Lowers Intraocular Pressure In Normotensive Dutch-Belted Rabbits, Samir Senapati, Ahmed Adel Ali Youssef, Corinne Sweeney, Chuntian Cai

Faculty and Student Publications

Cannabidiol (CBD) is the major non-psychoactive and most widely studied of the cannabinoid constituents and has great therapeutic potential in a variety of diseases. However, contradictory reports in the literature with respect to CBD’s effect on intraocular pressure (IOP) have raised concerns and halted research exploring its use in ocular therapeutics. Therefore, the current investigation aimed to further evaluate CBD’s impact on the IOP in the rabbit model. CBD nanoemulsions, containing Carbopol® 940 NF as a mucoadhesive agent (CBD-NEC), were prepared using hot-homogenization followed by probe sonication. The stability of the formulations post-moist-heat sterilization, in terms of physical and chemical …


Design Of Topical Moxifloxacin Mucoadhesive Nanoemulsion For The Management Of Ocular Bacterial Infections, Ahmed Adel Ali Youssef, Ruchi Thakkar, Samir Senapati, Poorva H. Joshi Jun 2022

Design Of Topical Moxifloxacin Mucoadhesive Nanoemulsion For The Management Of Ocular Bacterial Infections, Ahmed Adel Ali Youssef, Ruchi Thakkar, Samir Senapati, Poorva H. Joshi

Faculty and Student Publications

Ocular bacterial infections can lead to serious visual disability without proper treatment. Moxifloxacin (MOX) has been approved by the US Food and Drug Administration as a monotherapy for ocular bacterial infections and is available commercially as an ophthalmic solution (0.5% w/v). However, precorneal retention, drainage, and low bioavailability remain the foremost challenges associated with current commercial eyedrops. With this study, we aimed to design a MOX-loaded nanoemulsion (NE; MOX-NE) with mucoadhesive agents (MOX-NEM) to sustain MOX release, as well as to overcome the potential drawbacks of the current commercial ophthalmic formulation. MOX-NE and MOX-NEM formulations were prepared by hot homogenization …